Rationale: Homing of proangiogenic cells (PACs) is guided by chemoattractants and requires proteases to disrupt the extracellular matrix. The possibility that PAC recruitment involves an interaction between proteases and chemotactic factor receptors remains largely unexplored.
C irculating proangiogenic cells (PACs), a subset of mononuclear cells (MNCs), formerly referred to as endothelial progenitor cells, cooperate with resident endothelial cells (ECs) in the promotion of reparative neovascularization. Protease-rich PACs, at the forefront of the advancing endothelial bud, drill holes in the extracellular matrix for new vascular structures to expand and liberate extracellular matrix-bound growth factors and cytokines instrumental to tissue remodeling. 1 A reduction in the expression of metalloproteinase (MMP)9 and cathepsin L reportedly contributes to the impaired invasive capacity of PACs in diabetes. 2 The role of serine proteases in PAC-associated functions remains undefined.
Components of the kallikrein-kinin system (KKS), including the serine protease human tissue kallikrein (hK1), the substrate kininogen, and kinin receptors B 2 (B 2 R) (constitutive) and B 1 (B 1 R) (inducible), are expressed in vascular cells and leukocytes. 3 Genetic defects of the KKS result in impair-ment of reparative neovascularization and attenuation of inflammatory response. 4 -8 Forced hK1 gene (KLK1) expression, but not its loss-of-function polymorphic variant R53H-KLK1, induces capillary and arteriole growth by kinin receptor-dependent mechanisms. 6, 9, 10 Noteworthy, hK1 may also elicit angiogenic and cardioprotective actions through the B 2 R via a kinin-independent mechanism. 4, 11, 12 Recent studies identified a role for B 2 R and downstream phosphoinositide 3-kinase (PI3K)␥/Akt promigratory signaling in the recruitment of distinct populations of proangiogenic cells. [13] [14] [15] Here, we newly show that hK1 and B 2 R constitute essential cooperative elements of PACs invasive machinery.
Protein Levels and Activity
Immunoreactive hK1 and bradykinin (BK) were measured by ELISA. 9 HK1 enzymatic activity was assayed using colorimetric substrate S-2266 (Kabi Diagnostica). Western blotting (WB) and both in situ-and PAGE-zymographies were performed as described. 18, 19 Immunocytochemistry Samples were fixed, incubated with appropriate primary and secondary, fluorescence-conjugated antibodies, and microphotographs were acquired by a computer-imaging program.
Statistical Analysis
All results are expressed as meansϮSEM. Student t test was used for 2-group comparisons and ANOVA, followed by Bonferroni post hoc test, was used for multiple comparisons. A probability value of Ͻ0.05 was taken as statistically significant.
Results

Human PACs Express KLK1 mRNA and hK1 Protein
Q-RT-PCR showed that peripheral blood (PB) MNCs and culture-enriched PACs express KLK1 mRNA ( Figure 1A ). Flow cytometry confirmed hK1 expression on distinct PB-MNC subpopulations, including CD34 pos cells (30Ϯ5%), CD19 pos B lymphocytes (23Ϯ7%) and CD3 pos T lymphocytes (10Ϯ1%) ( Figure 1B , i). HK1 was also abundant in "nonclassic" CD16 pos /CD14 low monocytes (43Ϯ5%), but less in CD16 pos /CD14 high (9Ϯ3%) and CD16 neg /CD14 high monocytes (1.0Ϯ0.3%) ( Figure 1B , ii). Of note, MNCs cultured in the presence of hK1 inhibitor kallistatin lead to significantly lower PACs yields (PϽ0.05 versus control; Figure 1C ), suggesting a role of hK1 in the acquisition of PAC phenotype by MNCs. However, a cooperative contribution of hK1negative MNCs in PAC formation cannot be excluded. In fact, immunocytochemistry demonstrated that PACs com-prise both hK1 positive (60Ϯ19%) and hK1 negative elements ( Figure 1D ). Flow cytometry identified hK1 expression on both PACs cell membrane and cytosol ( Figure 1E ). Moreover, PACs secrete hK1 as documented by measuring immunoreactive protein (ELISA) and enzymatic activity (amidolytic assay) in conditioned medium ( Figure 1F ). We verified that PACs bind UEAI (Ulex europaeus I lectin), take up acetylated low-density lipoprotein (data not shown), and coexpress markers of endothelial/progenitor (CD34, CXCR4, and KDR) and hematopoietic cells (CD45, CD14, CD11b) ( Figure 1G ).
KLK1 Silencing Reduces PACs Invasive and Proangiogenic Capacities
To investigate endogenous hK1 functional relevance, human PACs were transfected with a pool of 4 specific small interfering KLK1 RNAs (siKLK1) (50 to 100 nmol/L) or scrambled sequences (control). Efficient KLK1 silencing was confirmed by reduction of mRNA, protein levels and enzymatic activity (PϽ0.05 versus control for all comparisons; Figure 2A ). Of note, KLK1 silencing reduced PAC migration and invasion abilities ( Figure 2B ) as well as their capacity to stimulate human umbilical vein endothelial cells (HUVECs) networking on Matrigel ( Figure 2C ; PϽ0.05 versus control 20 Using gel zymography, we observed reduced MMP2 gelatinolytic activity in siKLK1-PAC CM compared to control (PϽ0.05; Figure 2D ).
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HK1 Overexpression Enhances the Invasive and Proangiogenic Capacities and MMP2 Activity of PACs
Next, we investigated whether hK1-forced expression enhances PACs functions. HK1 overexpression after Ad.KLK1 infection was confirmed using Q-RT-PCR and WB of PACs lysates and by ELISA and amidolytic assay on PAC CM (PϽ0.05 versus Ad.Null for all comparisons; Online Figure I , A through D). Increased hK1 expression did not result however in increased levels of BK, the product of kininogen cleavage by hK1, in Ad.KLK1-PAC CM (Online Figure I , E). Forced hK1 expression conferred PACs with increased spontaneous motility (1.6-fold), invasive capacity (1.8-fold) and proangiogenic activity (1.4-fold) (PϽ0.05 versus Ad.Null for all comparisons; Figure 3A and 3B). In contrast, those functions remained unaltered in PACs infected with the catalytically defective polymorphic variant R53H-KLK1 (PϭNS versus Ad.Null; Figure 3A and 3B). Furthermore, KLK1-forced expression did not modify PACs ability to migrate toward SDF-1␣ and BK (data not shown).
To verify hK1/MMP2 functional association, we used both gel-and in situ-zymography, the latter using a FITC-conjugated gelatin system. Ad.KLK1-PACs showed enhanced MMP2 activity in both assays (PϽ0.05 versus Ad.Null or Ad.R53H; Figure 3C and 3D).
PACs Functional Enhancement by hK1 Is Mediated by B 2 R-and MMP-Dependent Mechanisms
For mechanistic interpretation of hK1-induced effects, we used hK1 and MMPs inhibitors and B 2 R signaling antagonists. Enhanced Ad.KLK1-PAC migration and invasion were both abrogated by the serine protease inhibitor aprotinin, the specific hK1 inhibitor kallistatin or the B 2 R antagonist icatibant (PϽ0.05 versus Ad.KLK1-PACs exposed to inhibitor vehicle (ctr) and PϭNS versus Ad.Null-PACs; Figure 4A , i and ii). Consistent with the data from icatibant, the B 2 Rselective antagonist MEN16132 (MEN), significantly inhibited the hK1-induced PACs migratory activity ( Figure 4A , iii). No inhibition was instead seen after B 1 R blockade with L-dAL-BK (PϭNS versus ctr and PϽ0.05 versus Ad.Null-PACs). Of note, both kallistatin and icatibant effectively decreased hK1-dependent MMP2 activation ( Figure 4B , i). In addition, hK1-transduced PACs invasive capacity was significantly reduced by MMP inhibitor, GM6001 (PϽ0.05 versus ctr and PϭNS versus Ad.Null-PACs; Figure 4B , ii). B 2 R-dependent activation of PAC migration is reportedly dependent on the PI3K/protein kinase B (PKB/Akt) signaling pathway. 13 We therefore investigated whether hK1-forced expression triggers a similar signaling mechanism. Akt phosphorylation (WB) and activity (ELISA) were both increased in Ad.KLK1-PACs, with this effect being blocked by icatibant (PϽ0.05 versus ctr and PϭNS versus Ad.Null-PACs; Figure  4C , i and ii). Unexpectedly, we did not find any change in the phosphorylation levels of eNOS (endothelial nitric oxide synthase) (at Ser1177 or Ser113) in Ad.KLK1-PACs (data not shown). At variance, we found inducible (i)NOS to be increased following Ad.KLK1 infection (PϽ0.05 versus Ad.Null; Figure  4C , iii). Furthermore, Ad.KLK1-PACs enhanced invasive capacity was significantly blunted by the PI3K␥ inhibitor AS605240, 14, 15 the NOS inhibitor N5-(1-Iminoethyl)-Lornithine dihydrochloride (LNIO) 21 or the nitric oxide (NO) scavenger 2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (c-PTIO) 22 (PϽ0.05 versus ctr and PϭNS versus Ad.Null-PACs; Figure 4C , iv).
Finally, Ad.KLK1-PACs ability to promote HUVEC networking was abolished by aprotinin and kallistatin, but preserved following B 2 R or B 1 R blockade or MMP inhibition ( Figure 4D ). In control experiments, BK (3ϫ10 Ϫ8 mol/L) did not affect HUVEC networking in the absence of PACs but increase network formation by 1.7-fold when PACs and HUVECs were cocultured, this effect blocked by icatibant (data not shown). Altogether, these data suggest that, although potentially responsive to kinin stimulation, Ad.KLK1-PACs may promote endothelial networking by hK1 direct effect on HUVECs or via proteolytic degradation of Matrigel.
Impaired Motility of KLK1-Knockout Lin neg MNCs and PACs
Next, we used null-mutant mice to further verify the importance of endogenous hK1 in MNC and PAC motility. Bone marrow (BM) lineage negative (Lin neg ) MNCs and PACs of wild type (WT) or KLK Ϫ/Ϫ mice were tested for migratory and proangiogenic activities. KLK Ϫ/Ϫ Lin neg MNCs and PACs showed normal spontaneous migration but were unresponsive to SDF-1␣ (PϽ0.05 versus WT; Figure 5A and 5B). Furthermore, KLK Ϫ/Ϫ PACs were less potent in promoting HUVEC networking ( Figure 5C ; PϽ0.05 versus WT). Of note, Ad.KLK1 increased KLK Ϫ/Ϫ PACs spontaneous and SDF-1␣-stimulated migration (PϽ0.05 versus Ad.Null; Figure 5B ). In contrast, in WT PACs, Ad.KLK1 supported spontaneous (PϽ0.05 versus Ad.Null) but not SDF-1␣-stimulated migration suggesting saturation of the cell migratory capacity (PϭNS versus Ad.Null; Figure 5B ). Finally, Ad.KLK1 increased KLK Ϫ/Ϫ PACs supporting action on HUVEC network formation, although to a lesser extent when compared to WT PACs (PϽ0.05 versus Ad.Null; Figure 5C ).
KLK1 Gene Deletion Impairs In Vivo Proangiogenic Action of BM-MNCs
Next, we evaluated whether KLK1 gene deletion negatively impacts on reparative angiogenesis. WT or KLK Ϫ/Ϫ BM-MNCs were intravenously injected in WT mice, 1 day after operative induction of unilateral limb ischemia. We observed a significant treatment-related effect on superficial blood flow recovery as assessed by Doppler flowmetry (PϽ0.01, ANOVA with repeated measurements). Post hoc analysis revealed that perfusion was improved by WT BM-MNCs but not by KLK Ϫ/Ϫ BM-MNCs as compared with vehicle ( Figure  6A ). Similarly, adductor muscle blood flow measurement using fluorescent microspheres denoted a significant improvement at 3 weeks with WT BM-MNCs, but not with KLK Ϫ/Ϫ BM-MNCs, over the vehicle ( Figure 6B ).
Immunofluorescence staining showed that capillary and arteriole density in the ischemic adductor muscle was significantly higher in WT BM-MNC-injected group compared with vehicle-or KLK Ϫ/Ϫ BM-MNC-treated groups ( Figure 6C ).
KLK1 Downregulation in Type 2 Diabetic PACs
PACs functionality is impaired in diabetes, but underpinning mechanisms remain largely undefined. 23 Because gene titration studies showed an effect of hK1 on distinct PACs activities, we next asked whether a defect in hK1 expression/ activity is implicated in type 2 diabetes (T2D)-PACs dysfunctional phenotype. Consistently, we found that diabetes reduces the abundance of hK1 pos cells within the PB-MNC pool, particularly in the CD34 pos subfraction. The intensity of the fluorescent signal was diminished in all studied populations (Online Figure II, A) . These changes were seen in the context of an overall decrease of specific PB-MNC subpopu- Figure II, B) and were mirrored by a remarkable reduction in EC-and monocyte-specific markers, ie, CD34, KDR, CXCR4, and CD14, on T2D-PACs compared with PACs from age-matched healthy controls (Online Figure II, C) . Of note, whereas KLK1 mRNA levels were comparable in T2D-and healthy PACs, hK1 protein levels were significantly reduced in T2D-PACs (Ϫ57%, PϽ0.05 versus healthy PACs; Figure 7A , i and ii), suggesting a post-transcriptional defect in hK1 synthesis. We next investigated microRNA (miR)-637, the only miR potentially implicated in inhibition of hK1 protein synthesis according to bioinformatics screening. However, we found no difference in mir637 expression between healthy and T2D-PACs ( Figure 7A , iii).
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KLK1 and B 2 R Genetic Engineering Rescues T2D-PACs Invasive Capacity
T2D-PACs manifested a remarkable reduction in migratory, invasive and network-forming potential (PϽ0.05 versus healthy PACs for all comparisons; Figure 7B and 7C), in line with previous reports. 24, 25 Ad.KLK1 infection of T2D-PACs resulted in a marked increase in KLK1 mRNA and secreted hK1 protein, similar to that of healthy Ad.KLK1-PACs (data not shown). Ad.KLK1 was able to enhance healthy PACs functions (PϽ0.05 versus Ad.Null), but failed to correct the defects observed in T2D-PACs (PϭNS versus Ad.Null) ( Figure 7B and 7C ). Furthermore, Ad.KLK1 failed to increase MMP2 activity in T2D-PAC CM ( Figure 7D) .
To determine the missing element accountable for the "diabetic block," we investigated the status of B 2 R in healthy and T2D-PACs. Flow cytometric analysis did not detect significant differences in B 2 R expression between the 2 groups ( Figure 8A, i) . Nevertheless, B 2 R-associated biological functions were remarkably impaired in diabetes. In fact, stimulation with the B 2 R ligand BK failed to increase T2D-PAC invasion capacity compared to healthy PACs, with this deficit being associated with reduced Akt activity ( Figure  8A , ii and iii).
Ad.B 2 R infection resulted in B 2 R increased mRNA and protein expression in PACs ( Figure 8B and 8C ). Both Ad.KLK1 and Ad.B 2 R increased the invasive capacity of healthy PACs (*PϽ0.05 versus Ad.Null), with no additive effect after combined infection ( Figure 8D ). In diabetes, neither Ad.KLK1 nor Ad.B 2 R alone improved PAC invasiveness, but in combination they remarkably rescued the diabetic phenotype (PϽ0.05 versus Ad.NullϩAd.Null; Figure 8D) , thus suggesting a cooperative hK1-B 2 R interaction.
Discussion
Classic chemoattractants/receptors pairs, like SDF-1␣/ CXCR4 and vascular endothelial growth factor/KDR, have been recently joined by the kinin/B 2 R pair as a potent mediator of PACs chemotaxis. 13 Furthermore, PACs use proteases, like MMPs and cathepsins, to disrupt the extracellular matrix in the initiation of reparative neovascularization. 2, 3, 26 However, the possibility that proteases could cooperate with chemokine receptors during PACs tissue invasion remains largely unexplored. Here, we reveal that hK1 coupling to B 2 R signaling is essential for PACs invasive capacity.
Despite persisting ambiguity about the precise circulating angiogenic/endothelial progenitors characteristics, CD34 is widely used for proangiogenic cells separation in human clinical trials. 27 Furthermore, CD34 progenitors level strictly correlates to cardiovascular risk, especially in patients with metabolic syndrome or diabetes. 23 Here, we demonstrate for the first time that, among freshly isolated MNCs, CD34 pos cells represent the subpopulation that most abundantly bears membrane-bound hK1. Furthermore, hK1 was abundantly expressed by nonclassic CD16 pos /CD14 low monocytes compared to CD16 neg /CD14 high monocytes. The respective role of these 2 populations in postischemic reparative processes is matter of debate. 28 The presence of hK1 in CD16 pos monocytes might add to their angiogenic potential, however this remains to be explored. Interestingly, B 2 R is also highly abundant in CD34 pos cells, 13 and CD16 monocytes. 29 HK1/ B 2 R coexpression on specific progenitors and monocyte fractions suggests that KKS components might cooperate during recruitment and homing. Importantly, hK1 inhibition by kallistatin results in remarkable reduction of PACs enrichment from cultured MNCs, in line with our previous observation of reduced Flk1 pos cKit pos progenitors production in BM of KLK1 Ϫ/Ϫ mice following limb ischemia induction. 4 Thus, hK1 might be a potential biomarker of MNCs differentiation into cellular phenotypes implicated in the modulation of vascular functions.
HK1 relevance in PACs functions was strengthened using silencing and viral vector-mediated overexpression approaches. Importantly, KLK1 gene titration data indicate that PAC migration, invasion, and proangiogenic activities concordantly increase with hK1 levels. The most acknowledged pathway mediating PAC migration centers on the kinase Akt. B 2 R and CXCR4 receptors engagement by kinin and SDF-1␣ on human PACs is associated with polarized recruitment and activation of PI3K␥ on the cell membrane, phosphorylation/activation of Akt and acquisition of a migratory phenotype. 13, 30 Of note, hK1 overexpression activates Akt in PACs and B 2 R blockade by icatibant suppresses Akt activation and invasive capacity of hK1-transduced PACs. Surprisingly, neither eNOS protein expression nor activation by phosphorylation on the 2 known regulating serine residues (Ser113 and Ser1177) was modulated by hK1-forced expression. Conversely, we here report for the first time that NOS inducible form, iNOS, is indeed constitutively expressed by PACs and enhanced by hK1 transduction. Furthermore, we show that NOS inhibition or NO scavenge both abrogate the enhanced invasive capacity of hK1-transduced PACs. This data indicates that PACs are equipped with sensors, eg, the B 2 R, to capture chemokine guidance signals, and enzymatic machinery, eg, hK1, coupled to B 2 R to enhance PAC motility. Furthermore, PACs-secreted hK1 could modify the extracellular environment and thus facilitate PACs and vascular cells tissue invasion. This latter mechanism is seemingly B 2 R-independent because kallistatin but not icatibant is able to block hK1-transduced PACs promoting EC networking on Matrigel. It would be interesting to verify whether the same signaling mechanism drives the homing of proinflammatory cells in ischemic tissues. Furthermore, we found that hK1 overexpression remarkably activates MMP2 through the B 2 R. Another MMP, MMP9, was shown to act as a downstream modulator of hK1 angiogenic activity in ischemia. 4 It is likely that the interaction of hK1 with different MMPs is context-dependent. For example, unlike MMP9, MMP2 is activated under nonischemic conditions, such as aging-related vascular remodeling. 31 To gain insight into KLK1 inherited defects, we verified the functional phenotype of BM-MNCs and PACs from KLK1 Ϫ/Ϫ mice. These mutant mice are reportedly unable to mount proper reparative angiogenesis and to mobilize Lin neg progenitors into the circulation after ischemia. 4 Our present data show for the first time that KLK1 Ϫ/Ϫ PACs are defective in their proangiogenic function, with such functional defect being ameliorated by hK1 transduction. In a mouse model of unilateral limb ischemia, KLK1 Ϫ/Ϫ BM-MNCs failed to stimulate vascular repair thus highlighting hK1 essential role in promotion of postischemic neovascularization. Furthermore, we found that engineering human PACs with wild type KLK1 improves their invasive and proangiogenic capacities, whereas gene transfer with the loss-of-function polymorphic R53H-KLK1 variant 32 is ineffective. This data complements previous work from our group demonstrating altered angiogenic/arteriogenic capacity of R53H-KLK1 in limb ischemia model. 4 R53H-KLK1 polymorphism is especially common in Afro-Caribbean individuals, but also present as a heterozygous trait in 7% of whites. It would be of paramount importance to verify whether subjects carrying R53H-KLK1 mutation are prone to more complicated postischemic outcomes because of reparative angiogenesis defects.
Finally, we investigated whether hK1 is implicated in T2D-PACs dysfunction. 25, 33 When comparing T2D-and healthy PACs, we found an unexpected diversity in EC- 
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and monocyte-specific surface markers expression, with decreased CD34 pos , KDR pos , CXR4 pos , and CD14 pos subsets in diabetes. Because these antigens are at least in part associated with highly chemotactic, proangiogenic MNCs, our results provide a possible key of interpretation for the reduced migratory and proangiogenic activity of T2D-MNCs. Of note, typical T2D-PACs dysfunction was associated with decreased hK1 protein, but normal KLK1 mRNA levels. This result points at a post-transcriptional alteration of hK1 in diabetes, in agreement with data showing that high glucose decreases PACs-cathepsin L activity without affecting its mRNA levels. 2 Different factors could cooperate to modulate hK1 expression in diabetes; ie, glycoxidation could interfere with protein translation/degradation processes. 34 In addition, miRs have been implicated in gene expression inhibition under different disease conditions, including diabetes. 35 Of note, KLK1 does not possess a strongly predicted interacting miR, but bioinformatics analysis showed miR637 to be associated, even if only poorly conserved. 36 However, we could not find any change of miR637 expression in T2D-PACs, thus further studies are needed to unravel the post-transcriptional mechanism of hK1 downregulation.
Surprisingly, hK1-forced expression could not revert the defective phenotype of T2D-PACs. Investigating possible causes for this failure, we found that the B 2 R is normally expressed on T2D-PACs, however it remains uncoupled from its downstream effector Akt. Noteworthy, combined hK1-B 2 R transduction did effectively rescue the impaired T2D-PACs invasive capacity. These data, supporting a key role of B 2 R in hK1-associated induction of PACs motility, introduces the new concept that implementation of functionally imperfect receptors by gene therapy could provide a means to restore proper coupling between components of the invasive machinery. It remains to be determined whether re-exposing transduced PACs to the diabetic environment may jeopardize their restored invasive function.
Taken together our results show for the first time that human PACs are equipped with active endogenous hK1 and that hK1 is crucial for PAC invasive and proangiogenic activities by both protease-and kinin receptor-mediated mechanisms. Importantly, PACs biological functions are impaired in conditions of hK1 deficit and restored by forced hK1 expression. Finally, this study demonstrates that KKS faulty components need to be repaired to restore the pristine PACs function in diabetes, thus providing the first proof of concept for multiple gene engineering of a pathway crucially implicated in angiogenesis. 
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